Healthcare Global Enterprises Limited (HCG) has updated its Investor Presentation for the quarter and nine months ended December 31, 2025 (Q3 & 9MFY26). This revised presentation supersedes the one initially filed on February 5, 2026, and incorporates certain clarifications and corrections. The company has provided a detailed operational and financial update, highlighting a 13% YoY revenue growth to ₹6,331 million in Q3 FY26, driven by an 8% increase in volumes and a 5% rise in Average Revenue Per Patient (ARPP). Adjusted EBITDA grew by 20% YoY to ₹1,108 million, with margins expanding to 17.5% from 16.5% in the previous year, attributed to operating leverage. The company also noted a 42% YoY revenue growth in its international business (Africa). HCG is strengthening its leadership team and expects its North Bangalore Greenfield Hospital, equipped with MR-LINAC technology, to commence operations by the end of Q4FY26. The nine-month period (9MFY26) saw a 16% YoY revenue growth to ₹18,931 million and a 20% YoY increase in Adjusted EBITDA to ₹3,458 million. The presentation also detailed the revenue mix by specialty and payor, with Medical Oncology contributing 38% and Cash + TPA accounting for 55% of revenues. Regional performance highlights include robust growth in the West cluster (17% YoY revenue growth) and continued momentum in the South cluster (9% YoY revenue growth). Capital expenditure for 9MFY26 stood at ₹2,227 million, and the net debt (including leases) was ₹15,451 million as of December 31, 2025.
